(Q46178748)

English

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Seok Lee

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Yoo-Jin Kim

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Nak-Gyun Chung

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Jihyang Lim

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Dong-Gun Lee

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Hee-Je Kim

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Chang-Ki Min

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Jong-Wook Lee

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Woo-Sung Min

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Chun-Choo Kim

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

language of work or name

0 references

publication date

1 February 2009

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

115

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

561-570

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic Stem Cell Transplantation in First Complete Remission Enhances Graft-versus-Leukemia Effect in Adults with Acute Lymphoblastic Leukemia: Antileukemic Activity of Chronic Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24026

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24026

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19117346

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46178748&oldid=2098486885"